CERVARIX
Manufacturer Details
GLAXO SMITH KLINE
Compositions:
Vaccine Human Papillomavirus Type 16 L1 protein 20mcg/ Vaccine Papillomavirus Type 18 L1 protein 20mcg/0.5ml ASO4 adjuvanted injection,
|
Strength
|
Rate
|
Packing Style
|
|
20mcg
|
2640.00
|
injection
|
List of Related Indications:
- Prevention of Cervical Cancer caused by HPV types 16 and 18
List Of Drugs:
- Vaccine Human Papillomavirus Type 16 and 18 (Recombinant )- Vaccine
Indication Type Description:
Drug Interaction:
Immunosuppressive therapies eg. irradiation . cyclotoxic drugs, and
coerticsteroids may reduce a patients immune response to the vaccine
Indication:
Prevention of cervical cancer caused by HPV types 16 and 18
Adverse Reaction:
Pain,redness and swelling at the injection site, fatigue, headache, fever,
myalgia, arthalgia
GI symptoms eg nausea, vomiting, diarrhea. abdominal pain,
urticaria, pruritus and rash
Hypersensitivity reactiuons including anaphylactic and anaphylactloid
angioedema
Contra-Indications:
Hypersensitivity
Special precautions-
Observe patients for 15 months after admininistion as syncope,
sometimes accompanied by transcient tonic clonic movements and
other seizure-like activity may occur during recovery
Caution in patients with thrombocytopenia or other coagulation
disorders as IM admin can cause bleeding .
Not to be administered by IV, SC or intravenous route.
Immunocompromised individuals may have diminished immune response
to the vaccine.As vaccination will not provide protection against every
HPV infection or existing HPV infection, routine cervical screening must be
performed.
Not recommended for use during pregnancy, caution in lactation
Dosages/ Overdosage Etc:
Prevention of cervical cancer caused by HPV Types 16 & 18
Dose-
Adult - Females 10-45 years
3 doses of 0.5ml each given at 0.1 & 6 months preferably administered into
deltoid muscle
Child- Not recommended for use in girls below 10 years of age.
